npj Breast Cancer

OCT 20, 2026 · JOURNAL ARTICLE

Tumor and ctDNA concordance of actionable alterations in metastatic breast cancer

npj Breast Cancer

As biomarker-driven therapies are available for hormone receptor-positive (HR+) metastatic breast cancer (MBC), identification of actionable alterations is critical for determining

OCT 19, 2026 · JOURNAL ARTICLE

Metaplastic breast carcinoma: a rare breast cancer with distinct biology and therapeutic challenges

npj Breast Cancer

Metaplastic breast carcinoma (MpBC) is a rare, histologically heterogeneous breast cancer typically treated with regimens developed for triple-negative breast cancer (TNBC), despit

OCT 17, 2026 · JOURNAL ARTICLE

Genome-wide CRISPR screen identifies mutation-specific pathways converging on TAZ/TEAD activation in mutant p53-driven breast cancer

npj Breast Cancer

Most clinical mutations of TP53 are missense mutations. We previously showed that TP53 -missense mutations common in triple-negative breast cancer (TNBC) patients produce neomorphi

OCT 14, 2026 · JOURNAL ARTICLE

Randomized clinical trial of self-acupressure for aromatase-inhibitor associated musculoskeletal symptoms

npj Breast Cancer

Abstract Half of aromatase inhibitor (AI)-treated patients with early stage breast cancer discontinue therapy early, primarily because of AI-associated musculoskeletal symptoms (AI

OCT 12, 2026 · JOURNAL ARTICLE

Construction of personal health knowledge graphs for clinical data harmonization in breast cancer

npj Breast Cancer

Integrating heterogeneous personal health data and maintaining clinical registries for breast cancer management is labor-intensive. This study presents an AI-powered virtual assist

OCT 9, 2026 · JOURNAL ARTICLE

Viral evolution of T1L mammalian orthoreovirus enhances breast cancer stem-like cell killing

npj Breast Cancer

Breast cancer stem-like cells (BCSCs) drive metastasis and therapy resistance, yet selective therapeutics to eliminate this quiescent population are lacking. We explored the potent

OCT 6, 2026 · JOURNAL ARTICLE

Key considerations for window of opportunity trials and preoperative endocrine therapy in breast cancer

npj Breast Cancer

Window of opportunity (WOO) trials are short, pre-surgical trials which aim to evaluate novel therapeutic strategies and answer biological and mechanistic questions. Despite their

SEP 30, 2026 · JOURNAL ARTICLE

Next-generation PARP1-selective inhibition and combination therapy in breast cancer

npj Breast Cancer

PARP inhibitors have transformed treatment of BRCA1/2 -mutated breast cancer but remain limited by acquired resistance, restricted activity in homologous recombination–proficient t